Solid Biosciences Inc. Research and Development Expense
Solid Biosciences Inc. (SLDB) reported Research and Development Expense of $44.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Solid Biosciences Inc. research and development expense for the quarter ending 2026-06-30 was $44.27M, a 36.56% increase year-over-year.
- Solid Biosciences Inc. research and development expense for the quarter ending 2026-03-31 was $46.14M, a 49.25% increase year-over-year.
- Solid Biosciences Inc. research and development expense for the quarter ending 2025-12-31 was $38.13M, a 23.94% increase year-over-year.
- Solid Biosciences Inc. research and development expense for the quarter ending 2025-09-30 was $38.86M, a 42.21% increase year-over-year.
- Solid Biosciences Inc. research and development expense for fiscal 2025 was $140.32M, a 45.52% increase from fiscal 2024.
- Solid Biosciences Inc. research and development expense for fiscal 2024 was $96.43M, a 25.95% increase from fiscal 2023.
- Solid Biosciences Inc. research and development expense for fiscal 2023 was $76.56M, a 2.37% decline from fiscal 2022.
- Solid Biosciences Inc. research and development expense for fiscal 2022 was $78.42M, a 33.51% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.27M 10-Q · filed 2026-08-06 | $90.41M 10-Q · filed 2026-08-06 | $128.54M derived: sum of 3 quarters · filed 2026-08-06 | $167.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $46.14M 10-Q · filed 2026-05-12 | $84.28M derived: sum of 2 quarters · filed 2026-05-12 | $123.14M derived: sum of 3 quarters · filed 2026-05-12 | $155.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $38.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $77.00M derived: sum of 2 quarters · filed 2026-03-19 | $109.41M derived: sum of 3 quarters · filed 2026-08-06 | $140.32M 10-K · filed 2026-03-19 |
| 2025-09-30 | $38.86M 10-Q · filed 2025-11-03 | $71.28M derived: sum of 2 quarters · filed 2026-08-06 | $102.19M 10-Q · filed 2025-11-03 | $132.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $32.41M 10-Q · filed 2026-08-06 | $63.33M 10-Q · filed 2026-08-06 | $94.10M derived: sum of 3 quarters · filed 2026-08-06 | $121.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $30.91M 10-Q · filed 2026-05-12 | $61.68M derived: sum of 2 quarters · filed 2026-05-12 | $89.01M derived: sum of 3 quarters · filed 2026-05-12 | $108.47M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $30.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $58.10M derived: sum of 2 quarters · filed 2026-03-19 | $77.56M derived: sum of 3 quarters · filed 2026-03-19 | $96.43M 10-K · filed 2026-03-19 |
| 2024-09-30 | $27.33M 10-Q · filed 2025-11-03 | $46.79M derived: sum of 2 quarters · filed 2025-11-03 | $65.66M 10-Q · filed 2025-11-03 | $81.11M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $19.46M 10-Q · filed 2025-08-12 | $38.33M 10-Q · filed 2025-08-12 | $53.79M derived: sum of 3 quarters · filed 2025-08-12 | $70.49M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $18.87M 10-Q · filed 2025-05-15 | $34.33M derived: sum of 2 quarters · filed 2025-05-15 | $51.03M derived: sum of 3 quarters · filed 2025-05-15 | $70.81M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $32.16M derived: sum of 2 quarters · filed 2025-03-06 | $51.93M derived: sum of 3 quarters · filed 2025-03-06 | $76.56M 10-K · filed 2025-03-06 |
| 2023-09-30 | $16.70M 10-Q · filed 2024-11-06 | $36.48M derived: sum of 2 quarters · filed 2024-11-06 | $61.11M 10-Q · filed 2024-11-06 | $82.40M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $19.78M 10-Q · filed 2024-08-13 | $44.41M 10-Q · filed 2024-08-13 | $65.70M derived: sum of 3 quarters · filed 2024-08-13 | $79.70M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $24.63M 10-Q · filed 2024-05-15 | $45.92M derived: sum of 2 quarters · filed 2024-05-15 | $59.93M derived: sum of 3 quarters · filed 2024-05-15 | $83.11M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $21.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $35.30M derived: sum of 2 quarters · filed 2024-03-13 | $58.48M derived: sum of 3 quarters · filed 2024-03-13 | $78.42M 10-K · filed 2024-03-13 |
| 2022-09-30 | $14.01M 10-Q · filed 2023-11-08 | $37.19M derived: sum of 2 quarters · filed 2023-11-08 | $57.13M 10-Q · filed 2023-11-08 | $71.72M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $23.18M 10-Q · filed 2023-08-14 | $43.13M 10-Q · filed 2023-08-14 | $57.72M derived: sum of 3 quarters · filed 2024-03-13 | $72.14M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $19.95M 10-Q · filed 2023-05-11 | $34.54M derived: sum of 2 quarters · filed 2024-03-13 | $48.97M derived: sum of 3 quarters · filed 2024-03-13 | $64.48M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $14.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $29.02M derived: sum of 2 quarters · filed 2024-03-13 | $44.53M derived: sum of 3 quarters · filed 2024-03-13 | $58.74M 10-K · filed 2024-03-13 |
| 2021-09-30 | $14.43M 10-Q · filed 2022-11-10 | $29.94M derived: sum of 2 quarters · filed 2022-11-10 | $44.14M 10-Q · filed 2022-11-10 | $59.87M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $15.51M 10-Q · filed 2022-08-11 | $29.72M 10-Q · filed 2022-08-11 | $45.44M derived: sum of 3 quarters · filed 2023-03-23 | $61.49M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | $14.21M 10-Q · filed 2022-04-27 | $29.93M derived: sum of 2 quarters · filed 2023-03-23 | $45.97M derived: sum of 3 quarters · filed 2023-03-23 | $59.42M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $15.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $31.77M derived: sum of 2 quarters · filed 2023-03-23 | $45.22M derived: sum of 3 quarters · filed 2023-03-23 | $64.88M 10-K · filed 2023-03-23 |
| 2020-09-30 | $16.05M 10-Q · filed 2021-11-03 | $29.49M derived: sum of 2 quarters · filed 2021-11-03 | $49.16M 10-Q · filed 2021-11-03 | $76.22M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | $13.45M 10-Q · filed 2021-08-16 | $33.11M 10-Q · filed 2021-08-16 | $60.18M derived: sum of 3 quarters · filed 2022-03-14 | $82.97M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | $19.66M 10-Q · filed 2021-05-14 | $46.73M derived: sum of 2 quarters · filed 2022-03-14 | $69.52M derived: sum of 3 quarters · filed 2022-03-14 | $91.13M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | $27.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $49.86M derived: sum of 2 quarters · filed 2022-03-14 | $71.47M derived: sum of 3 quarters · filed 2022-03-14 | $94.74M 10-K · filed 2022-03-14 |
| 2019-09-30 | $22.79M 10-Q · filed 2020-11-05 | $44.40M derived: sum of 2 quarters · filed 2020-11-05 | $67.67M 10-Q · filed 2020-11-05 | $85.43M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $21.61M 10-Q · filed 2020-08-06 | $44.88M 10-Q · filed 2020-08-06 | $62.64M derived: sum of 3 quarters · filed 2021-03-15 | $77.32M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $23.27M 10-Q · filed 2020-05-07 | $41.03M derived: sum of 2 quarters · filed 2021-03-15 | $55.71M derived: sum of 3 quarters · filed 2021-03-15 | $69.31M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $17.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $32.44M derived: sum of 2 quarters · filed 2021-03-15 | $46.04M derived: sum of 3 quarters · filed 2021-03-15 | $57.97M 10-K · filed 2021-03-15 |
| 2018-09-30 | $14.68M 10-Q · filed 2019-11-12 | $28.27M derived: sum of 2 quarters · filed 2019-11-12 | $40.20M 10-Q · filed 2019-11-12 | $52.15M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $13.59M 10-Q · filed 2019-08-14 | $25.52M 10-Q · filed 2019-08-14 | $37.47M derived: sum of 3 quarters · filed 2020-03-12 | $48.09M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $11.93M 10-Q · filed 2019-05-13 | $23.88M derived: sum of 2 quarters · filed 2020-03-12 | $34.49M derived: sum of 3 quarters · filed 2020-03-12 | $43.10M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $11.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $22.57M derived: sum of 2 quarters · filed 2020-03-12 | $31.17M derived: sum of 3 quarters · filed 2020-03-12 | $39.91M 10-K · filed 2020-03-12 |
| 2017-09-30 | $10.62M 10-Q · filed 2018-11-13 | $19.23M derived: sum of 2 quarters · filed 2018-11-13 | $27.96M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $8.61M 10-Q · filed 2018-08-10 | $17.34M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $8.73M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $20.12M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |